skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
BH3 Mimetic ABT-737 (Code C114384)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: BH3 Mimetic ABT-737

Definition: An orally bioavailable, selective small molecule B-cell lymphoma 2 (Bcl-2) Homology 3 (BH3) mimetic, with potential pro-apoptotic and antineoplastic activities. ABT-737 binds to the hydrophobic groove of multiple members of the anti-apoptotic Bcl-2 protein family, including Bcl-2, Bcl-xl and Bcl-w. This inhibits the activity of these pro-survival proteins and restores apoptotic processes in tumor cells, via activation of Bak/Bax-mediated apoptosis. The pro-survival Bcl-2 proteins are overexpressed in many cancers and play important roles in the regulation of apoptosis. Their expression is associated with increased drug resistance and tumor cell survival. ABT-737 does not inhibit the pro-survival proteins Mcl-1, Bcl-B, Bfl-1 (A1); therefore, tumors that overexpress these Bcl-2 family proteins are resistant to ABT-737.

Label: BH3 Mimetic ABT-737

NCI Thesaurus Code: C114384 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C1570187  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Benzamide, 4-(4-((4'-Chloro(1,1'-biphenyl)-2-yl)methyl)-1-piperazinyl)-n-((4-(((1r)-3-(dimethylamino)-1-((phenylthio)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-
BH3 Mimetic ABT-737

External Source Codes: 
PDQ Closed Trial Search ID 758552
PDQ Open Trial Search ID 758552 (check for NCI PDQ open clinical trial info)
UMLS CUI C1570187

Other Properties:
     Name Value (qualifiers indented underneath)
code C114384
Contributing_Source FDA
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom